A Calcitonin-Negative Neuroendocrine Tumor Derived from Follicular Lesions of the Thyroid

被引:7
作者
Kim, Ga Young [1 ]
Park, Chul Yun [1 ]
Cho, Chang Ho [2 ]
Park, June Sik [3 ]
Dal Jung, Eui [1 ]
Jeon, Eon Ju [1 ]
机构
[1] Catholic Univ Daegu, Sch Med, Dept Internal Med, 33 Duryugongwon Ro 17 Gil, Daegu 705718, South Korea
[2] Catholic Univ Daegu, Sch Med, Dept Pathol, Daegu, South Korea
[3] Catholic Univ Daegu, Sch Med, Dept Otolaryngol Head & Neck Surg, Daegu, South Korea
关键词
Calcitonin; Carcinoma; medullary; Neuroendocrine tumors;
D O I
10.3803/EnM.2015.30.2.221
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neuroendocrine lesions of the thyroid are rare. The most common types are medullary thyroid carcinomas (MTCs) and C-cell hyperplasia. MTCs originate from thyroid parafollicular cells that secrete calcitonin which serves as a serum marker of MTCs. Here, the rare case of a calcitonin-negative neuroendocrine tumor (NET) derived from follicular lesions of the thyroid is described. A 34-year-old man presented at our hospital for the surgical management of an incidental thyroid nodule that was observed on an ultrasound sonography (USG) of the neck. Initially, USG-guided aspiration cytology was performed, and a MTC was suspected. The expressions of thyroglobulin and thyroid transcription factor-1, which are thyroid follicular cell markers, and synaptophysin and chromogranin A, which are neuroendocrine markers, was confirmed following surgical pathology. However, the staining of calcitonin, a marker of MTCs, was not observed. A nonmedullary NET of the thyroid is uncommon, and the distinction between calcitonin-negative NETs and MTCs of the thyroid may be important due to differences in their clinical courses and management.
引用
收藏
页码:221 / 225
页数:5
相关论文
共 17 条
  • [1] Solid tumors associated with multiple endocrine neoplasias
    Almeida, Madson Q.
    Stratakis, Constantine A.
    [J]. CANCER GENETICS AND CYTOGENETICS, 2010, 203 (01) : 30 - 36
  • [2] Unusual tumors of the thyroid gland
    Baloch, Zubair W.
    LiVolsi, Virginia A.
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2008, 37 (02) : 297 - +
  • [3] Baloch ZW, 2001, AM J CLIN PATHOL S1, V115, P56
  • [4] Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma
    Bockhorn, M
    Frilling, A
    Rewerk, S
    Liedke, M
    Dirsch, O
    Schmid, KW
    Broelsch, CE
    [J]. THYROID, 2004, 14 (06) : 468 - 470
  • [5] Calcitonin-Negative Neuroendocrine Tumor of the Thyroid: A Distinct Clinical Entity
    Chernyavsky, Victoriya S.
    Farghani, Saima
    Davidov, Tomer
    Ma, Ly
    Barnard, Nicola
    Amorosa, Louis F.
    Trooskin, Stanley Z.
    [J]. THYROID, 2011, 21 (02) : 193 - 196
  • [6] Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders
    Elisei, R
    Bottici, V
    Luchetti, F
    Di Coscio, G
    Romei, C
    Grasso, L
    Miccoli, P
    Iacconi, P
    Basolo, F
    Pinchera, A
    Pacini, F
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) : 163 - 168
  • [7] MEDULLARY THYROID CARCINOMA
    Griebeler, Marcio L.
    Gharib, Hossein
    Thompson, Geoffrey B.
    [J]. ENDOCRINE PRACTICE, 2013, 19 (04) : 703 - 711
  • [8] Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO
  • [9] 2-1
  • [10] Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
    Kloos, Richard T.
    Eng, Charis
    Evans, Douglas B.
    Francis, Gary L.
    Gagel, Robert F.
    Gharib, Hossein
    Moley, Jeffrey F.
    Pacini, Furio
    Ringel, Matthew D.
    Schlumberger, Martin
    Wells, Samuel A., Jr.
    [J]. THYROID, 2009, 19 (06) : 565 - 612